A recent retrospective cohort study revealed that dupilumab was successful in treating bullous pemphigoid (BP). The study, which was conducted from Jan. 1, 2021, to Jul. 31, 2022, included 146
Ava T. Shamban, MD, is a board-certified dermatologist with over 20 years of experience in the field. A scientist, researcher, and business owner, Dr. Shamban’s goal is to help her
In a recent study published in the British Journal of Dermatology, it was found that for patients with moderate psoriasis, treatment with risankizumab demonstrated superior efficacy compared to apremilast. AbbVie’s
During a recent systematic review, researchers determined that compound glycyrrhizin tablets combined with the 308 nm excimer laser proved more effective in treating vitiligo than using the laser alone. The
Study reveals that retinol-containing topical neck cream significantly improved signs of aging by reducing lines, wrinkles, and crepiness.
Alphyn Biologics recently announced results from the first cohort of its Phase 2a clinical trial of AB-101a in treating atopic dermatitis.
Almirall’s study shows tildrakizumab (Ilumetri®) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis.
The FDA has approved cantharidin (YCANTH™) for the treatment of molluscum contagiosum in pediatric and adult patients.
The clinical trial of ritlecitinib reports the drug demonstrated efficacy, improvement, and an acceptable safety profile.
Incyte announces positive results from its trial evaluating the safety and efficacy of ruxolitinib cream in pediatric patients with AD.
Data from Boehringer Ingelheim’s Effisayil 2 reveal that spesolimab significantly reduced the risk for generalized pustular psoriasis flares.
Galderma’s Olympia 2 study evaluating the safety and efficacy of nemolizumab in patients with prurigo nodularis shows positive results.
UNION therapeutics has announced positive topline results from its study of oral orismilast in adult patients with hidradenitis suppurativa.
Researchers have developed a breakthrough method enabling the early detection of infant atopic dermatitis known as ‘RNA monitoring’.
The FDA has cleared Candela’s Vbeam 595 nm Pulsed Dye Laser to treat port wine stains and hemangiomas in pediatric patients.
The FDA has approved ritlecitinib (LITFULO™) for patients aged 12 years and above with severe alopecia areata.
A recent study evaluated how REVIVV®could help patients with androgenetic alopecia improve their quality of life and emotional wellbeing.
A study evaluating the efficacy of diacerein 1% for epidermolysis bullosa simplex revealed it did not outperform vehicle in study endpoints.
New study maps the hidden features of inflammation in psoriatic disease, explaining the drivers behind disease severity.
Results of a Phase 3 clinical trial of guselkumab shows improvement in all minimal disease activity in adults with psoriatic arthritis.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
